Logo-ipp

Immunopathol Persa. 2022;8(1): e19. doi: 10.34172/ipp.2022.19

Review

Lung cancer risk and the inhibitors of angiotensin converting enzyme; an updated review on recent evidence

Maryam Khosravian 1 ORCID, Mahnaz Momenzadeh 2 * ORCID, Farzad Koosha 3 ORCID, Niloufar Alimohammadi 4 ORCID, Neda Kianpour 5 ORCID

Cited by CrossRef: 4

1- Osouleddini N, Noei M, Rahimianshahreza N. Employing metal-doped carbon nanocones for the drug delivery of purinethol anticancer: Insights from DFT calculations. Diamond and Related Materials. 2023;132:109641 [Crossref]
2- Arabpour J, Rezaei K, Khojini J, Razi S, Hayati M, Gheibihayat S. The potential role and mechanism of circRNAs in Ferroptosis: A comprehensive review. Pathology - Research and Practice. 2024;255:155203 [Crossref]
3- Ghasemi Darestani N, Gilmanova A, Al-Gazally M, Zekiy A, Ansari M, Zabibah R, Jawad M, Al-Shalah S, Rizaev J, Alnassar Y, Mohammed N, Mustafa Y, Darvishi M, Akhavan-Sigari R. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commun Signal. 2023;21(1) [Crossref]
4- Yang M, Zhang Y, Li M, Liu X, Darvishi M. The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies. Cancer Cell Int. 2023;23(1) [Crossref]
5- Bao S, Darvishi M, H Amin A, Al-Haideri M, Patra I, Kashikova K, Ahmad I, Alsaikhan F, Al-qaim Z, Al-Gazally M, Kiasari B, Tavakoli-Far B, Sidikov A, Mustafa Y, Akhavan-Sigari R. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment. J Cancer Res Clin Oncol. 2023;149(10):7945 [Crossref]